Healthcare marketing research firm G&S Research promoted Mike Bandick to SVP. The move follows a company restructuring that put Bandick at the head of R&S Research's client solutions group.
George Grubb, principal of G&S Research, said in a statement that Bandick's leadership has been “instrumental in navigating the complex opportunities and recent economic contraction of the biopharmaceutical market space that we serve.”
Bandick joined R&S Research in 2006 as VP and business unit leader, and will remain a member of the company's executive committee. Prior to joining R&S Research, Bandick was senior director of marketing for Suros Surgical Systems, which was acquired by Hologic. Before that, Bandick worked in several capacities with Eli Lilly, and was most recently a global marketing director on Cymbalta, Lilly's antidepressant and pain treatment. He also worked on Zyprexa, Lilly's schizophrenia and bipolar drug.